Applying Quality by Design for Extended Release Hydrophilic Matrix Tablets - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Applying Quality by Design for Extended Release Hydrophilic Matrix Tablets
This study examines the effect and interaction of variations in hypromellose physicochemical properties.


Pharmaceutical Technology
Volume 36, Issue 10, pp. 106-116

References

1. L.X. Yu, Pharm. Res. 25(4), 781–791 (2008).

2. T.D. Cabelka et al., "Application of Quality by Design Principles to the Formulation of aHydrophilic Matrix Tablet of a High Dose/High Solubility Drug," presented at the AAPS Annual Meeting (Los Angeles, 2009).

3. T.D Cabelka et al., "Application of Quality by Design Principles to the Formulation of Extended-Release Propranolol Hydrochloride Hydrophilic Matrix Tablets," presented at the AAPS Annual Meeting (New Orleans, 2010).

4. H. Deng et al., "Application of Quality by Design Principles to the Formulation of Extended-Release Theophylline Hydrophilic Matrix Tablets," presented at the CRS Annual Meeting and Exposition (National Harbor, Maryland, 2011).

5. A.S. Rathore and H. Winkle, Nature Biotechnol. 27 (1) 26–34 (2009).

6. ICH, ICH Q8(R2) Pharmaceutical Development (2009).

7. USP 30–NF 25, "USP Monographs: Hypromellose," online, http://www.uspnf.com/, accessed May 10, 2008.

8. J.E. Hogan, Drug Dev. Ind. Pharm. 15 (6), 975–1999 (1989).

9. P. Gao et al., J. Pharm. Sci. 85 (7), 732–740 (1996).

10. M. Levina and A.R. Rajabi-Siahboomi, J. Pharm. Sci. 93 (11), 2746–2754 (2004).

11. K. Mitchell et al., Int. J. Pharm. 66 (1–3), 233–242 (1990).

12. A.R. Rajabi-Siahboomi, A. Nokhodchi, and M.H. Rubinstein, "Compaction Behavior of Hydrophilic Cellulose Ether Polymers," in Pharm. Technol. Yearbook: Tableting and Granulation (1998), pp. 32–40 .

13. R.W. Korsmeyer et al., Int. J. Pharm. 15 (1), 25–35 (1983).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here